Quick Answer
CV Sciences, Inc. reported Total Revenue of $13.79 million for fiscal year 2025.
CV Sciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $13.79M -12.2% |
$15.71M -1.9% |
$16.00M -1.2% |
$16.20M -19.2% |
$20.05M -17.9% |
$24.43M -54.5% |
| Revenue (ASC 606) | $13.79M -12.2% |
$15.71M -1.9% |
$16.00M -1.2% |
$16.20M -19.2% |
$20.05M -17.9% |
$24.43M -54.5% |
| Net Income | -$958.0K +60.0% |
-$2.39M -177.2% |
$3.10M +137.8% |
-$8.21M +47.2% |
-$15.55M +30.2% |
-$22.28M -34.2% |
| Diluted EPS | -$0.01 +0.0% |
-$0.01 -150.0% |
$0.02 +128.6% |
-$0.07 +50.0% |
-$0.14 +36.4% |
-$0.22 -29.4% |
| Total Assets | $6.96M -12.2% |
$7.93M -13.8% |
$9.20M -27.8% |
$12.74M -29.5% |
$18.07M -41.0% |
$30.62M -41.9% |
| Cash and Equivalents | — | — | — | $611.0K -55.6% |
$1.38M -65.8% |
$4.02M -55.8% |
| Long-Term Debt | $387.0K | $0.00 | — | — | — | — |
| Stockholders Equity | $1.47M -18.2% |
$1.79M -38.2% |
$2.90M +473.6% |
-$777.0K -121.9% |
$3.54M -68.4% |
$11.21M -61.5% |
| R&D Expense | $122.0K +3.4% |
$118.0K -21.9% |
$151.0K -50.8% |
$307.0K -74.1% |
$1.19M -59.7% |
$2.94M -49.9% |
| Operating Income | -$470.0K +78.5% |
-$2.19M -165.2% |
$3.36M +149.1% |
-$6.85M +62.9% |
-$18.45M +18.4% |
-$22.59M -31.0% |
| Gross Profit | $6.75M -5.8% |
$7.17M +1.2% |
$7.08M +27.7% |
$5.55M -35.6% |
$8.62M -21.7% |
$11.01M -68.6% |
| Shares Outstanding | 184.26M +0.0% |
184.26M +14.0% |
161.68M +6.3% |
152.10M +35.2% |
112.48M +11.7% |
100.66M +1.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.26M | -15.8% | -10.1% |
| Revenue (ASC 606) | September 30, 2025 | $3.26M | -15.8% | -10.1% |
| Net Income | September 30, 2025 | -$382.0K | +16.2% | -46.4% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $7.00M | -16.6% | -12.0% |
| Cash and Equivalents | September 30, 2022 | $1.14M | — | +2.2% |
| Long-Term Debt | September 30, 2025 | $504.0K | — | +142.3% |
| Stockholders Equity | September 30, 2025 | $1.54M | -29.8% | -14.6% |
| R&D Expense | September 30, 2025 | $24.0K | -17.2% | -52.0% |
| Operating Income | September 30, 2025 | -$275.0K | +19.4% | -109.9% |
| Gross Profit | September 30, 2025 | $1.58M | -11.2% | -14.4% |
| Shares Outstanding | September 30, 2025 | 184.26M | +0.0% | +0.0% |
- CV Sciences, Inc. reported Total Revenue of $13.79 million for fiscal year 2025.
- CV Sciences, Inc. showed a decrease of -12.2% in Total Revenue compared to the prior fiscal year.
- CV Sciences, Inc. reported Revenue (ASC 606) of $13.79 million for fiscal year 2025.
- CV Sciences, Inc. showed a decrease of -12.2% in Revenue (ASC 606) compared to the prior fiscal year.
- CV Sciences, Inc. reported Net Income of -$958.0 thousand for fiscal year 2025.
- CV Sciences, Inc. showed an increase of +60.0% in Net Income compared to the prior fiscal year.
- CV Sciences, Inc. reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
- CV Sciences, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- CV Sciences, Inc. reported Total Assets of $6.96 million for fiscal year 2025.
- CV Sciences, Inc. showed a decrease of -12.2% in Total Assets compared to the prior fiscal year.
- CV Sciences, Inc. reported Cash and Equivalents of $611.0 thousand for fiscal year 2022.
- CV Sciences, Inc. showed a decrease of -55.6% in Cash and Equivalents compared to the prior fiscal year.
- CV Sciences, Inc. reported Long-Term Debt of $387.0 thousand for fiscal year 2025.
- CV Sciences, Inc. reported Stockholders Equity of $1.47 million for fiscal year 2025.
- CV Sciences, Inc. showed a decrease of -18.2% in Stockholders Equity compared to the prior fiscal year.
- CV Sciences, Inc. reported R&D Expense of $122.0 thousand for fiscal year 2025.
- CV Sciences, Inc. showed an increase of +3.4% in R&D Expense compared to the prior fiscal year.
- CV Sciences, Inc. reported Operating Income of -$470.0 thousand for fiscal year 2025.
- CV Sciences, Inc. showed an increase of +78.5% in Operating Income compared to the prior fiscal year.
- CV Sciences, Inc. reported Gross Profit of $6.75 million for fiscal year 2025.
- CV Sciences, Inc. showed a decrease of -5.8% in Gross Profit compared to the prior fiscal year.
- CV Sciences, Inc. reported Shares Outstanding of 184.26 million shares for fiscal year 2025.
- CV Sciences, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: